Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECiprofloxacinhydrochloridemonohydrateCat.No.:HY-B0356BCASNo.:86393-32-0Synonyms:Bay-09867hydrochloridemonohydrate分?式:C??H??ClFN?O?分?量:385.82作?靶點:Topoisomerase;Apoptosis;Antibiotic;Bacterial;MitochondrialMetabolism;ReactiveOxygenSpecies作?通路:CellCycle/DNADamage;Apoptosis;Anti-infection;MetabolicEnzyme/Protease;Immunology/Inflammation;NF-κB儲存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實驗DMSO:5mg/mL(12.96mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.5919mL12.9594mL25.9188mL5mM0.5184mL2.5919mL5.1838mL10mM0.2592mL1.2959mL2.5919mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥0.5mg/mL(1.30mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥0.5mg/mL(1.30mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥0.5mg/mL(1.30mM);ClearsolutionBIOLOGICALACTIVITY?物活性Ciprofloxacin(Bay-09867)hydrochloridemonohydrate?種?服有效的拓撲異構(gòu)酶IV抑制劑。Ciprofloxacinhydrochloridemonohydrate誘導(dǎo)線粒體DNA和核DNA損傷并導(dǎo)致線粒體功能障礙和活性氧產(chǎn)?。Ciprofloxacinhydrochloridemonohydrate具有抗增殖活性并誘導(dǎo)細胞凋亡(apoptosis)。Ciprofloxacinhydrochloridemonohydrate?種氟喹諾酮類抗?素，具有強?的抗活性。IC50&TargetQuinolone體外研究Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(5-50μg/mL;0-24h;tendoncells)inhibitscellproliferationandcausescellcyclearrestattheG2/Mphase[1].Ciprofloxacin(Bay-09867)hydrochloridemonohydrateshowspotentactivityagainstY.pestisandB.anthraciswithMIC90of0.03μg/mLand0.12μg/mL,respectively[2].CellViabilityAssay[1]CellLine:TendoncellsConcentration:5,10,20and50μg/mLIncubationTime:24hoursResult:Decreasedthecellularityoftendoncells.CellCycleAnalysis[1]CellLine:TendoncellsConcentration:50μg/mLIncubationTime:24hoursResult:ArrestedcellcycleattheG2/Mphaseandinhibitedcelldivisionintendoncells.WesternBlotAnalysis[1]CellLine:TendoncellsConcentration:50μg/mLIncubationTime:0,6,12,17and24hours2/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEResult:Down-regulatedtheexpressionofCDK-1andcyclinBproteinandmRNA.Up-regulatedtheexpressionofPLK-1protein.體內(nèi)研究Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(30mg/kg;i.p.;for24hours;BALB/cmice)hasprotectionagainstY.pestisinmurinemodelofpneumonicplague[3].Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(100mg/kg;i.g.;daily,for4weeks;C57BL/6Jmice)acceleratesaorticrootenlargementandincreasestheincidenceofaorticdissectionandrupturebydecreasesLOXlevelandincreasesMMPlevelsandactivityintheaorticwall[4].Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(100mg/kg;i.g.;daily,for4weeks;C57BL/6Jmice)inducesDNAdamageandreleaseofDNAtothecytosol,mitochondrialdysfunction,andactivationofcytosolicDNAsensorsignaling.Ciprofloxacinlactateincreasesapoptosisandnecroptosisintheaorticwall[4].AnimalModel:BALB/cmice[3]Dosage:30mg/kgAdministration:Intraperitonealinjection;for24hoursResult:Reducedthelungbacterialloadinmurinemodelofpneumonicplague.AnimalModel:C57BL/6Jmice[4]Dosage:100mg/kgAdministration:Oralgavage;daily,for4weeksResult:HadaorticdestructionthatwasaccompaniedbydecreasedLOXexpressionandincreasedMMPexpressionandactivity.AnimalModel:C57BL/6Jmice[4]Dosage:100mg/kgAdministration:Oralgavage;daily,for4weeksResult:CausedmitochondrialDNAandnuclearDNAdamage,leadingtomitochondrialdysfunctionandROSproduction.Increasedapoptosisandnecroptosisintheaorticwall.戶使?本產(chǎn)品發(fā)表的科研?獻?NatCommun.2022Mar2;13(1):1116.?AdvSci(Weinh).2020Jul21;7(17):2001374.?IntJAntimicrobAgents.2018Aug;52(2):269-271.3/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?EBioMedicine.2022Apr;78:103943.?MicrobiolSpectr.2022Apr25:e0251821.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].TsaiWC,et,al.Ciprofloxacin-mediatedcellproliferationinhibitionandG2/Mcellcyclearrestinrattendoncells.ArthritisRheum.2008Jun;58(6):1657-63.[2].SteenbergenJ,et,al.InVitroandInVivoActivityofOmadacyclineagainstTwoBiothreatPathogens,BacillusanthracisandYersiniapestis.AntimicrobAgentsChemother.2017Apr24;61(5):e02434-16.[3].HamblinKA,et,al.InhaledLiposomalCiprofloxacinProtectsagainstaLethalInfectioninaMurineModelofPneumonicPlague.FrontMicrobiol.2017Feb6;8:91.[4].LeMaireSA,et,al.EffectofCiprofloxacinonSusceptibilitytoAorticDissectionand